4-bromo-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)benzene | 1401774-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-bromo-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)benzene
• 英文别名: 3-[1-(4-bromophenyl)-1H-[1,2,3]triazol-4-yl]propan-1-ol；3-[1-(4-bromophenyl)triazol-4-yl]propan-1-ol
• CAS: 1401774-24-0
• 化学式: C₁₁H₁₂BrN₃O
• 分子量: 282.14
• InChiKey: KONMCLWCDLDWFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)benzene 、 3-(trans-2-[2]pyridyl-vinyl)-aniline 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二环己基磷-2,4,6-三异丙基联苯 potassium carbonate 作用下， 以 叔丁醇 为溶剂， 反应 20.0h， 以70%的产率得到3-(1-{4-[3-(2-pyridin-2-ylvinyl)phenylamino]phenyl}-1H-[1,2,3]triazol-4-yl)propan-1-ol
  参考文献：
  名称：

  Compounds for use as therapeutic agents affecting p53 expression and/or activity

  摘要：

  本发明涉及化合物(I)，其中R1和R2分别代表氢原子，(C1-C4)烷氧基，氟代(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基，或-NHCO苯基；R3、R4和R5分别代表氢原子，(C1-C4)烷基，CONHR6基团，-CONR7R8基团，-SO2NHR6基团，或杂环烷基，可选择地被卤原子取代，-(CH2)nNR7R8基团或羟基(C1-C4)烷基；R6代表氢原子，-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基，可选择地被羟基取代；或其药学上可接受的盐之一，用作预防、抑制或治疗患有该疾病的患者的药剂，所述疾病涉及到p53蛋白的失调。其中一些化合物是新的，也是本发明的一部分。

  公开号：

  EP2505198A1
• 作为产物：
  描述：

  4-戊炔-1-醇 、 对溴碘苯 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium carbonate 、 sodium ascorbate 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 16.0h， 以53%的产率得到4-bromo-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)benzene
  参考文献：
  名称：

  Compounds for use as therapeutic agents affecting p53 expression and/or activity

  摘要：

  本发明涉及化合物(I)，其中R1和R2分别代表氢原子，(C1-C4)烷氧基，氟代(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基，或-NHCO苯基；R3、R4和R5分别代表氢原子，(C1-C4)烷基，CONHR6基团，-CONR7R8基团，-SO2NHR6基团，或杂环烷基，可选择地被卤原子取代，-(CH2)nNR7R8基团或羟基(C1-C4)烷基；R6代表氢原子，-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基，可选择地被羟基取代；或其药学上可接受的盐之一，用作预防、抑制或治疗患有该疾病的患者的药剂，所述疾病涉及到p53蛋白的失调。其中一些化合物是新的，也是本发明的一部分。

  公开号：

  EP2505198A1

文献信息

• COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY
  申请人：Scherrer Didier

  公开号：US20140206690A1

  公开（公告）日：2014-07-24

  The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C 1 -C 4 )alkoxy group, a fluoro(C 1 -C 4 )alkoxy group, a hydroxyl group, a benzyloxy group, a di(C 1 -C 4 )alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C 1 -C 4 )alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO 2 NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH 2 ) n NR7R8 group or a hydroxy(C 1 -C 4 )alkyl group; R6 represents a hydrogen atom, a —(CHR9) m (CH 2 ) n NR7R8 group or a (C 1- C 6 )alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中R1和R2分别表示氢原子，(C1-C4)烷氧基，氟(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基或—NHCO苯基；R3，R4和R5分别表示氢原子，(C1-C4)烷基，CONHR6基，—CONR7R8基，—SO2NHR6基或杂环基，所述杂环基可选地被卤原子，—(CH2)nNR7R8基或羟基(C1-C4)烷基取代；R6表示氢原子，—(CHR9)m( )nNR7R8基或(C1-C6)烷基，可选地被羟基取代；或其药学上可接受的盐之一，用于预防，抑制或治疗患有p53失调的患者的疾病的方法。其中一些化合物是新的，也是本发明的一部分。
• Compounds for use as therapeutic agents affecting P53 expression and/or activity
  申请人：ABIVAX

  公开号：US10538485B2

  公开（公告）日：2020-01-21

  The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

  本公开涉及化合物 (I) 其中 R1 和 R2 独立地代表氢原子、(C1-C4)烷氧基、氟(C1-C4)烷氧基、羟基、苄氧基、二(C1-C4)烷基氨基、吡啶基乙烯基、嘧啶基乙烯基、苯乙烯基或 -NHCOphenyl 基；R3、R4 和 R5 各自代表氢原子、(C1-C4)烷基、CONHR6 基团、-CONR7R8 基团、-SO2NHR6 基团或任选被卤素原子、-(CH2)nNR7R8 基团或羟基(C1-C4)烷基取代的杂芳基；R6代表氢原子、-(CHR9)m( )nNR7R8基团或任选被羟基取代的(C1-C6)烷基；或其任何药学上可接受的盐，用于预防、抑制或治疗患者的疾病，所述疾病涉及p53失调。其中一些化合物是新化合物，也是本公开的一部分。
• Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity
  作者：Dipti Kanabar、Pamela Farrales、Abbas Kabir、Daniel Juang、Manu Gnanmony、Joseph Almasri、Nicolas Torrents、Snehal Shukla、Vivek Gupta、Vikas V. Dukhande、Amber D'Souza、Aaron Muth

  DOI：10.1016/j.bmcl.2020.127372

  日期：2020.9

  Gankyrin is an oncoprotein overexpressed in numerous cancer types and appears to play a key role in regulating cell proliferation, cell growth, and cell migration. These roles are largely due to gankyrin's protein-protein interaction with the 26S proteasome. We previously published a study exploring the aryl sulfonate ester of cjoc42 in an effort to enhance gankyrin binding and inhibit cancer cell proliferation. In order to further improve the gankyrin binding ability of the cjoc42 scaffold, an extensive SAR for the aryl-triazole moiety of cjoc42 was developed. Our cjoc42 derivatives exhibited enhanced gankyrin binding, as well as enhanced antiproliferative activity against Hep3B, HepG2, A549, and MDA-MB-231 cancer cell lines.
• US9890112B2
  申请人：——

  公开号：US9890112B2

  公开（公告）日：2018-02-13
• [EN] COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY<br/>[FR] COMPOSÉS POUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES AFFECTANT L'EXPRESSION ET/OU L'ACTIVITÉ DE P53
  申请人：SPLICOS SOC

  公开号：WO2012131656A2

  公开（公告）日：2012-10-04

  The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl- vinyl group, a pyrimidinyl- vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.